Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform offers integrated technologies, which processes for the scalable production of lentiviral vectors. The inAAVate offers an end-to-end platform, integrates proprietary technologies across construct design, upstream and downstream processing, analytics, and fill/finish. The Company's solutions include process development, GMP manufacturing, analytical methods, and regulatory support.